Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 7-13 , April 2010

Comparison of clinical-metabolic monitoring and outcomes and coronary risk status in people with type 2 diabetes from Australia, France and Latin America

  • Juan J. Gagliardino

      Affiliations

    • Center of Experimental and Applied Endocrinology (CENEXA, National University of La Plata-National Research Council of La Plata), PAHO/WHO Collaborating Center for Diabetes Research, Education, and Care, La Plata, Argentina
    • Corresponding Author InformationCorresponding author at: CENEXA (UNLP-CONICET LA PLATA), Facultad de Ciencias Médicas, UNLP - Calles 60 y 120, 1900 La Plata, Argentina. Tel.: +54 221 4236712; fax: +54 221 4222081.
    • ,
  • Line Kleinebreil

      Affiliations

    • Georges Pompidou Hospital, Paris, France
    • ,
  • Stephen Colagiuri

      Affiliations

    • Department of Endocrinology, Diabetes and Metabolism, Prince of Wales Hospital, Randwick, NSW, Australia
    • ,
  • Jeff Flack

      Affiliations

    • Department of Endocrinology, Diabetes and Metabolism, Prince of Wales Hospital, Randwick, NSW, Australia
    • ,
  • Joaquín E. Caporale

      Affiliations

    • Center of Experimental and Applied Endocrinology (CENEXA, National University of La Plata-National Research Council of La Plata), PAHO/WHO Collaborating Center for Diabetes Research, Education, and Care, La Plata, Argentina
    • ,
  • Fernando Siri

      Affiliations

    • Center of Experimental and Applied Endocrinology (CENEXA, National University of La Plata-National Research Council of La Plata), PAHO/WHO Collaborating Center for Diabetes Research, Education, and Care, La Plata, Argentina
    • ,
  • Charles Clark Jr.

      Affiliations

    • Indiana University School of Medicine, Division of Continuing Medical Education, Indianapolis, USA
    • This manuscript was prepared by above authors on behalf of the ANDIAB, the DIABCARE and the QUALIDIAB Net participating centers.

Received 22 June 2009 ,Revised 17 December 2009 ,Accepted 22 December 2009.

References 

  1. Mc Carty D, Zimmet P. Diabetes 1994 to 2010. Global Estimates and Projections. Melbourne, Australia: International Diabetes Institute; 1994;
  2. J. Gagliardino, E. Olivera. The regions and their health care systems: Latin American, in: W. Gruber, T. Lander, B. Leese, T. Songer, H. Williams (Eds.), Economics of Diabetes and Diabetes Care. A Report of the Diabetes Health Economics Study Group, 1997, pp. 51–59.
  3. Gagliardino JJ, De La Hera M, Siri F. Evaluación preliminar de la calidad de atención de personas con diabetes en Argentina. Rev. Soc. Arg. Diabetes. 2001;35:121–133
  4. Grant RW, Buse JB, Meigs JB, University HealthSystem Consortium Diabetes Benchmarking Project Team . Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–342
  5. The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. 1993;329:977–986
  6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853
  7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 2003;238:383–393
  8. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N. Engl. J. Med. 2008;358:580–591
  9. ADVANCE Collaborative Group , Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560–2572
  10. Action to Control Cardiovascular Risk in Diabetes Study Group , Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008;358:2545–2559
  11. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation. 2009;119:351–357
  12. Ray KK, Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772
  13. Herman WH, Eastman RC. The effects of treatment on the direct costs of diabetes. Diabetes Care. 1998;21(Suppl.3):C19–C24
  14. Piwernetz K, Home PD, Staehr Johansen K, Kleinebreil L, Vermeij D, Storms GEMG. DIABCARE Quality Network in Europe. TELEMATICS Project within the St. Vincent Declaration. Consensus Meeting. Diab. Nutr. Metab. 1995;8:243–249
  15. Gagliardino JJ. Una iniciativa de la DOTA para implementar el control de calidad de atención (QUALIDIAB) en América Latina y el Caribe. Revista de la ALAD. 2000;8:26–35
  16. J.R. Flack, S. Colagiuri, on behalf of the National Association of Diabetes Centres, Australian National Diabetes Information Audit & Benchmarking [ANDIAB] 2000. Final Report, September 2000.
  17. IDF Clinical Guidelines Task Force . Global Guideline for Type 2 Diabetes. Brusells: International Diabetes Federation; 2005;
  18. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963–1972
  19. Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR, et al. ACE/AACE Diabetes Recommendations Implementation Writing Committee, ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr. Pract. 2006;12(Suppl. 1):6–12
  20. Cull CA, Manley SE, Stratton IM, Neil HA, Ross IS, Holman RR, et al. Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin. Chem. 1997;43:1913–1918
  21. Wood D, De Baker G, Faegerman O, Grahan I, Mancia G, Pyorala K. Together with Members of the Task Force, Prevention of coronary disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Eur. Heart J. 1998;19:1434–1503
  22. Gudbjornsdottir S, Cederholm J, Nilson PM, Eliasson B. Steering Committee of the Swedish National Diabetes Register. The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003;26:1270–1276
  23. World Health Organization, WHO, Obesity. Preventing and Managing the Global Epidemic. Report of the WHO Consultation of Obesity, World Health Organisation. Geneva, WHO, 1998.
  24. Grundy S, Cleeman J, Merz CN, Brewer HB, Clark LT, Hunninghake DB, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227–239
  25. Mazze R, Deeb L, Palumbo PJ. Altering physicians’ practice patterns—a nationwide educational experiment: evaluation of the Clinical Education Program of the American Diabetes Association. Diabetes Care. 1986;9:420–425
  26. Gagliardino J, Etchegoyen G, PEDNID-LA Research Group . A model education program for people with type 2 diabetes: a cooperative Latin-American implementation study. Diabetes Care. 2001;24:1001–1007
  27. Norris S, Lau J, Smith S, Schmid C, Engelgau M. Self-management education for adults with type 2 diabetes: a meta-analysis of the effect on glycemic control. Diabetes Care. 2002;25:1159–1171
  28. Gagliardino JJ, Olivera E, Etchegoyen GS, Guidi ML, Caporale JE, Martella A, et al. PROPAT: a study to improve the quality and reduce the cost of diabetes care. Diabetes Res. Clin. Pract. 2006;72:284–291
  29. CDC Diabetes Cost-effectiveness Group . Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA. 2002;287:2542–2551

☆ Source of financial support: The QUALIDIAB project was sponsored by the Declaration of the Americas (DOTA), with funds from Becton Dickinson and Company, Eli Lilly and Company, LifeScan Inc, Novo Nordisk A/S, and Roche Diagnostics. ANDIAB was supported by Servier Laboratories and the Australian Government Department of Health and Ageing.

PII: S0168-8227(09)00549-X

doi: 10.1016/j.diabres.2009.12.024

Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 7-13 , April 2010

Article Tools